Urine Drug Testing and Its Impact on the Opioid Crisis
Title: Urine Drug Testing and Its Impact on the Opioid Crisis
Originally Aired: Tuesday, June 18, 2019
Time: 1 p.m. ET
Presenter: Jeffrey Fudin, B.S., Pharm.D., FCCP, FASHP
Unless otherwise noted, P.A.C.E.™ accreditation will expire six months after the live webinar.
Protect the Health of Your Patients
An estimated 2.4 million people in the United States have opioid-use disorders and more than 42,000 die from opioid-related overdoses every year. In light of this epidemic, clinicians can face legal risks if patients are not screened and monitored during opioid treatment. To help combat the crisis and aid clinicians, the U.S. Centers for Disease Control (CDC), Centers for Medicare and Medicaid Services (CMS), and the American Association for Clinical Chemistry (AACC) have developed guidelines for screening and monitoring patients who take prescription opioids.
In this P.A.C.E.-accredited Fisher Healthcare webinar, Jeffrey Fudin, B.S., Pharm.D., FCCP, FASHP, will discuss the testing guidelines and best practices for screening and monitoring patients who take prescription opioids. He will review cases that demonstrate the positive impact of screening on patient care and describe how opioid testing protocols can be implemented in your facility.
This webinar will help you:
- Describe the differences between qualitative (in-office) and quantitative (laboratory) testing
- Identify the legal risks if patients are not screened and monitored while taking prescription opioids
- Explain how to interpret unexpected urine drug testing (UDT) results
- Explain how to make UDT results part of ongoing clinical assessment and decision making
This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E. Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.
Jeffrey Fudin, B.S., Pharm.D., FCCP, FASHP
Dr. Fudin is a Clinical Pharmacy Specialist and Director at Stratton VA Medical Center in Albany, New York, and the Chief Executive and Chief Medical Officer of Remitigate in Delmar, New York. He serves on the New York State Board of Medicine Office of Professional Conduct, and as adjunct faculty at Western New England University’s College of Pharmacy and Albany College of Pharmacy and Health Sciences.
Dr. Fudin earned his B.A. and Pharm.D. from Albany College of Pharmacy and Health Sciences and completed an oncology and hematology fellowship at the SUNY/Upstate Medical Center. With over 30 years of experience in acute pain management, Dr. Fudin is considered a national expert in pharmacogenetics, forensic pharmacy, and advanced pain therapeutics. He has helped to develop practice guidelines for the use of opioids in chronic non-cancer pain and international guidelines for opioid-induced constipation, urine drug monitoring, arthritis, fibromyalgia, and palliative care.
Dr. Fudin has been published more than 300 times in peer-reviewed journals and textbooks, and has been invited to speak nationally on various pain-management topics.